Antimicrobial resistance in Streptococcus pneumoniae: Implications for patients with community-acquired pneumonia

Mayo Clinic Proceedings

Volumn 75, Issue 11, 2000, Pages 1161-1168

  Chenoweth, Carol E ^a,e   Saint, Sanjay ^b   Martinez, Fernando ^c   Lynch III, Joseph P ^d   Mark Fendrick, A ^c  

^a Division of Infectious Diseases Laboratory   (United States)

^b Division of General Medicine

^c Division of Pulmonary Medicine

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; STRAIN DIFFERENCE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0033761135     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/75.11.1161     Document Type: Review

References (75)

1. Lave JR, Lin CJ, Fine Mi, Hughes-Cromwick P. The cost of treating patients with community-acquired pneumonia. Semin Kespir Crit Care Med. 1999;20:189-197.
2. Marston BJ, Plouffe JF, File TM Jr,et al,Community-Based Pneumonia Incidence Study Group. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med. 1997; 157: 1709-1718.
3. Rahav G, Toledano Y, Engelhard D,et al. Invasive pneumococcal infections: a comparison between adults and children. Medicine (Baltimore). 1997;76:295-303.
4. Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumonias the leading cause of pneumonia of unknown etiology? a microbiologie study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999;106:385-390.
5. Hofmann J, Cetron MS, Parley MM,et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995:333:481-486.
6. Hibbs JR, Douglas JM Jr, Judson FN, McGill WL, Rietmeijer CA, Janoff EN. Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994. Clin Infect Dis. 1997;25:195-199.
7. Ortqvist A, Valtonen M, Cars O, Wahl M, Saikku P, Jean C, Scandinavian Sparfloxacin Study Group. Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin. Chest. 1996:110:1499-1506.
8. Pallares R, Linares J, Vadillo M,et al. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N EnglJ Med. 1995:333:474-480.
9. Chenoweth C, Lynch JP III. Antimicrobial resistance: implications for managing respiratory failure. Curr Opin Pulm Med. 1997;3: 159-169.
10. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program. Clin Infect Dis. 1998:27:764-770.
11. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl JMed. 1996:335:1445-1453.
12. Jones RN, Low DE, Pfaller MA. Epidemiologie trends in nosocomial and community-acquired infections due to antibioticresistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis. 1999;33:101112.
13. Moreno S, Garcia-Leoni ME, Cercenado E, Diaz MD, Bernaldo de Quiros JC, Bouza E. Infections caused by erythromycin-resistant Streptococcus pneumoniae: incidence, risk factors, and response to therapy in a prospective study. Clin Infect Dis. 1995;20:11951200.
14. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D,et al. Multivariate analysis of risk factors for infection due to penicillinresistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis. 1997:24:1052-1059.
15. Appelbaum PC. Epidemiology and in vitro susceptibility of drugresistant Streptococcus pneumoniae. Pediatr Infect Dis J. 1996; 15: 932-934.
16. Blondeau JM. A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolones." JAntimicrob Chemother. 1999;43(suppl B):l-l 1.
17. Casellas JM, Gilardoni M, Tome G,et al. Comparative in-vitro activity of levofloxacin against isolates of bacteria from adult patients with community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1999;43(suppl C):37-42.
18. Thomson KS, Chartrand SA, Sanders CC, Block SL. In-vitro activity of levofloxacin against Streptococcus pneumoniae with various levels of penicillin resistance. J Antimicrob Chemother. 1999;43 (supplC):15-19.
19. Chen DK, McGeer A, de Azavedo JC, Low DE, Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999; 341:233-239.
20. Novak R, Henriques B, Charpentier E, Normark S, Tuomanen E. Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature. 1999:399:590-593.
21. McCullers JA, English BK, Novak R. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis. 2000; 181:369-373.
22. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologie studies did not affect outcome in adults hospi-talized with community-acquired pneumonia. Am J Respir Cril CareMed. 1999;160:346-348.
23. Rhew DC, Riedinger MS, Sandhu M, Bowers C, Greengold N, Weingarten SR. A prospective, multicenter study of a pneumonia practice guideline. Chest. 1998;114:115-119.
24. Bartlett JG, Breiman RF, Mandell LA, File TM Jr, Infectious Diseases Society of America. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis. 1998:26:811838.
25. Niederman MS, Bass JB Jr, Campbell CD,et al,American Thoracic Society, Medical Section of the American Lung Association. Guidelines for the initial management of adults with communityacquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis. 1993:148:1418-1426.
26. Barry AL. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in North America. Am J Med. 1999; 107 (1A):28S-33S.
27. Tomasz A. New faces of an old pathogen: emergence and spread of multidrug-resistant Streptococcus pneumoniae. Am J Med. 1999; 107(IA):55S-62S.
28. Chambers HF. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis. 1999;179(suppl 2): S353-S359.
29. Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997-98. Emerg Infect Dis. 1999:5:757-765.
30. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis. 1992:15:77-83.
31. Doern GV, Brueggemann AB, Blocker M,et al. Clonal relationships among high-level penicillin-resistant Streptococcus pneumoniae in the United States. Clin Infect Dis. 1998;27:757-761.
32. Pallares R, Gudiol F, Linares J,et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med. 1987;317:18-22.
33. Ortqvist A. Pneumococcal disease in Sweden: experiences and current situation. Am J Med. 1999;107(1A):44S-49S.
34. Centers for Disease Control and Prevention. Geographic variation in penicillin resistance in Streptococcus pneumoniae-selected sites. United States, 1997. MMWR Morb Mortal Wkly Rep. 1999; 48:656-661.
35. Spika JS, Facklam RR, Plikaytis BD, Oxtoby MJ, Pneumococcal Surveillance Working Group. Antimicrobial resistance of Streptococcus pneumoniae in the United States, 1979-1987. J Infect Dis. 1991:163:1273-1278.
36. Jorgensen JH, Doern GV, Mäher LA, Howell AW, Redding JS. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother. 1990; 34:2075-2080.
37. Breiman RF, Butler JC, Tenover FC, Elliott JA, Facklam RR. Emergence of drug-resistant pneumococcal infections in the United States. JAMA. 1994;271:1831-1835.
38. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother. 1994;38:24192425.
39. Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF. The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System. J Infect Dis. 1996; 174:986-993.
40. Doern GV, Brueggemann A, Holley HP Jr, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother. 1996:40:1208-1213.
41. Thornsberry C, Ogilvie PT, Holley HP Jr, Sahm DF. In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance. ClinTher. 1998;20:1179-1190.
42. Nuorti JP, Butler JC, Crutcher JM,et al. An outbreak of multidrug-resistant pneumococcal pneumonia and bacteremia among unvaccinated nursing home residents. N EngI J Med. 1998;338: 1861-1868.
43. Hoefnagels-Schuermans A, Van Eldere J, Van Lierde S, Verbist L, Verhaegen J, Peetermans WE. Increase in penicillin resistance rates in Belgium due to clonal spread of a penicillin-resistant 23F Streptococcus pneumoniae strain. Eur J Clin Microbiol Infect Dis. 1999; 18:120-125.
44. Deeks SL, Palacio R, Ruvinsky R,et al,Streptococcus pneumoniae Working Group. Risk factors and course of illness among children with invasive penicillin-resistant Streptococcus pneumoniae. Pediatrics. 1999;103:409-413.
45. Syrogiannopoulos GA, Grivea IN, Beratis NG,et al. Resistance patterns of Streptococcus pneumoniae from carriers attending daycare centers in southwestern Greece. Clin Infect Dis. 1997;25:188-194.
46. Bedos JP, Chevret S, Chastang C, Geslin P, Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis. 1996;22:63-72.
47. Nava JM, Bella F, Garau J,et al. Predictive factors for invasive disease due to penicillin-resistant Streptococcus pneumoniae: a population-based study. Clin Infect Dis. 1994:19:884-890.
48. McDougal LK, Rasheed JK, Biddle JW, Tenover FC. Identification of multiple clones of extended-spectrum cephalosporin-resistant Streptococcus pneumoniae isolates in the United States. Antimicrob Agents Chemother. 1995;39:2282-2288.
49. Jones RN, Pfaller MA. Bacterial resistance: a worldwide problem. Diagn Microbiol Infect Dis. 1998:31:379-388.
50. Kaplan SL, Mason EO Jr. Management of infections due to antibiotic-resistant Streptococcus pneumoniae. Clin Microbiol Rev. 1998; 11:628-644.
51. Cizman M, Pokorn M, Seme K, Paragi M, Orazem A. Influence of increased macrolide consumption on macrolide resistance of common respiratory pathogens. Eur J Clin Microbiol Infect Dis. 1999; 18:522-524.
52. Jacobs MR. Increasing importance of antibiotic-resistant Streptococcus pneumoniae in acute otitis media. Pediatr Infect Dis J. 1996:15:940-943.
53. Fasola EL, Bajaksouzian S, Appelbaum PC, Jacobs MR. Variation in erythromycin and clindamycin susceptibilities of Streptococcus pneumoniae by four test methods. Antimicrob Agents Chemother. 1997:41:129-134.
54. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med. 1999; 159: 266-270.
55. Turnidge J. Pharmacokinetics and phartnacodynamics of fluoroquinolones. Drugs. 1999;58(suppl 2):29-36.
56. Plouffe JF, Franklin County Pneumonia Study Group. Levofloxacin in vitro activity against bacteremic isolates of Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 1996;25:43-45.
57. Baquero F, Garcia-Rodriguez JA, Garcia de Lomas J, Aguilar L, Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance of 1,113 Streptococcus pneumoniae isolates from patients with respiratory tract infections in Spain: results of a 1-year (1996-1997) multicenter surveillance study. Antimicrob Agents Chemother. 1999:43:357-359.
58. Nightingale CH. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologie and pharmacokinetic-pharmacodynamic characteristics. Phannacotherapy. 2000;20:245-256.
59. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicmb Agents Chemother. 1997;41:101-106.
60. Liljequist BO, Hoffman BM, Hedlund J. Activity of trovafloxacin against blood isolates of Streptococcus pneumoniae in Sweden. Eur J Clin Microbiol Infect Dis. 1996; 15:671 -675.
61. Campbell GD Jr, Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis. 1998;26:1188-1195.
62. Plouffe JF, Breiman RF, Facklam RR, Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae: implications for therapy and prevention. JAMA. 1996;275:194-198.
63. Heffelfinger JD, Dowell SF, Jorgensen JH,et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med. 2000; 160:13991408.
64. Ewig S, Ruiz M, Torres A,et al. Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med. 1999; 159:1835-1842.
65. Metlay JP, Hofmann J, Cetron MS,et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis. 2000;30:520528.
66. Bouza E. Antibiotic resistance and therapeutic options in lower respiratory tract infections. Int JAntimicrob Agents. 1999;! l(suppl 1):S3-S6.
67. Siegel RE. The significance of serum vs tissue levels of antibiotics in the treatment of penicillin-resistant Streptococcus pneumoniae and community-acquired pneumonia: are we looking in the wrong place? Chest. 1999;! 16:535-538.
68. Amsden GW, Graci DM, Cabelus LJ, Hejmanowski LG. A randomized, crossover design study of the pharmacology of extendedspectrum fluoroquinolones for pneumococcal infections. Chest. 1999:116:115-119.
69. Fine MJ, Stone RA, Singer DE,et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med. 1999:159:970-980.
70. Gilbert K, Gleason PP, Singer DE,et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am JMed. 1998; 104:17-27.
71. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med. 1999:159:2562-2572.
72. Ednie LM, Visalli MA, Jacobs MR, Appelbaum PC. Comparative activities of clarithromycin, erythromycin, and azithromycin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother. 1996:40:1950-1952.
73. File TM Jr, Segreti J, Dunbar L,et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41:1965-1972.
74. Jones RN, Pfaller MA, Doern GV, Erwin ME, Hollis RJ, Cefepime Study Group. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis. 1998:30:215-228.
75. Clemett D, Markham A. Linezolid. Drugs. 2000;59:815-827.